MUC16 and cancer: Cluster analysis identified a pro-cancer role for the ERS high-risk subgroup, which had lower mutation rates of key genes (SPOP and MUC16), multiple low-expressed immune-related molecules, and differential expression in macrophages (M1 and M2).